(Q43654284)

25 November 2017

title

Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles (English)

1 reference

25 November 2017

0 references

M Berton

1

1 reference

25 November 2017

P Turelli

2

1 reference

25 November 2017

D Trono

3

1 reference

25 November 2017

C A Stein

4

1 reference

25 November 2017

E Allémann

5

1 reference

25 November 2017

R Gurny

6

1 reference

25 November 2017

publication date

1 August 2001

1 reference

25 November 2017

published in

Pharmaceutical Research

1 reference

25 November 2017

volume

18

1 reference

25 November 2017

issue

8

1 reference

25 November 2017

page(s)

1096-1101

1 reference

Cellular delivery of antisense oligonucleotides

25 November 2017

cites work

1 reference

12 December 2020

The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

1 reference

12 December 2020

Novel mechanisms for antisense-mediated regulation of gene expression

1 reference

12 December 2020

Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking

1 reference

12 December 2020

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms

1 reference

12 December 2020

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

12 December 2020

Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture

1 reference

12 December 2020

A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA

1 reference

12 December 2020

Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides

1 reference

12 December 2020

Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine.

1 reference

12 December 2020

Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro.

1 reference

12 December 2020

Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides

1 reference

12 December 2020

Molecular mechanisms of action of antisense drugs

1 reference

12 December 2020

Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex

1 reference

12 December 2020

Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides

1 reference

12 December 2020

PAMAM dendrimers as delivery agents for antisense oligonucleotides

1 reference

12 December 2020

Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides

1 reference

12 December 2020

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

12 December 2020

Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide

1 reference

12 December 2020

Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization

1 reference

12 December 2020

Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides

1 reference

12 December 2020

Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro

1 reference

12 December 2020

Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles

1 reference

12 December 2020

Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

HIV-1 Reverse Transcription A Termination Step at the Center of the Genome

1 reference

12 December 2020

Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.

1 reference

12 December 2020

HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway

1 reference

12 December 2020

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

1 reference

12 December 2020

A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010962507273

1 reference

25 November 2017

1 reference